Laboratory of Immunology and Biotherapy, Department Human Pathology, University of Messina, Italy; Cellular Therapy Program, University Hospital - A.O.U. Policlinico, Messina, Italy.
Immunol Lett. 2013 Sep-Oct;155(1-2):6-10. doi: 10.1016/j.imlet.2013.09.021. Epub 2013 Sep 26.
Advances in immunobiology knowledge as well as in cell culture processes that generate large numbers of purified and functionally mature dendritic cells (DCs) have raised the possibility that DCs might represent promising clinical agents to generate effective immune responses against cancer. Here, we discuss the present pitfalls of dendritic cell vaccines for the treatment of human cancer with regard to the most recent knowledge in the biology of DCs. In particular, we highlight the relevance of improving our current understanding of DC trafficking, functions and interactions with other cells of innate immunity for the development of more effective cancer vaccines.
免疫生物学知识的进步以及能够大量生成纯化和功能成熟树突状细胞（DC）的细胞培养工艺，使得 DC 有可能成为产生针对癌症的有效免疫反应的有前途的临床制剂。在这里，我们根据 DC 生物学的最新知识，讨论了树突状细胞疫苗在治疗人类癌症方面目前存在的问题。特别是，我们强调了改善我们对 DC 迁移、功能以及与先天免疫的其他细胞相互作用的现有理解对于开发更有效的癌症疫苗的相关性。
